These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
185 related articles for article (PubMed ID: 32591138)
1. [Metastatic squamous cell carcinomas of the anal canal: Current management and prospects]. Saint A; Evesque L; François É Bull Cancer; 2020; 107(7-8):792-799. PubMed ID: 32591138 [TBL] [Abstract][Full Text] [Related]
2. Docetaxel, cisplatin, and fluorouracil chemotherapy for metastatic or unresectable locally recurrent anal squamous cell carcinoma (Epitopes-HPV02): a multicentre, single-arm, phase 2 study. Kim S; François E; André T; Samalin E; Jary M; El Hajbi F; Baba-Hamed N; Pernot S; Kaminsky MC; Bouché O; Desrame J; Zoubir M; Ghiringhelli F; Parzy A; De La Fouchardiere C; Smith D; Deberne M; Spehner L; Badet N; Adotevi O; Anota A; Meurisse A; Vernerey D; Taieb J; Vendrely V; Buecher B; Borg C Lancet Oncol; 2018 Aug; 19(8):1094-1106. PubMed ID: 30042063 [TBL] [Abstract][Full Text] [Related]
3. Recurrent metastatic anal cancer treated with modified paclitaxel, ifosfamide, and cisplatin and third-line mitomycin/cetuximab. Khawandanah M; Baxley A; Pant S J Oncol Pharm Pract; 2015 Jun; 21(3):232-7. PubMed ID: 24627343 [TBL] [Abstract][Full Text] [Related]
4. Atezolizumab plus modified docetaxel-cisplatin-5-fluorouracil (mDCF) regimen versus mDCF in patients with metastatic or unresectable locally advanced recurrent anal squamous cell carcinoma: a randomized, non-comparative phase II SCARCE GERCOR trial. Kim S; Buecher B; André T; Jary M; Bidard FC; Ghiringhelli F; François É; Taieb J; Smith D; de la Fouchardière C; Desramé J; Samalin E; Parzy A; Baba-Hamed N; Bouché O; Tougeron D; Dahan L; El Hajbi F; Jacquin M; Rebucci-Peixoto M; Spehner L; Vendrely V; Vernerey D; Borg C BMC Cancer; 2020 Apr; 20(1):352. PubMed ID: 32334548 [TBL] [Abstract][Full Text] [Related]
5. The role of systemic chemotherapy and multidisciplinary management in improving the overall survival of patients with metastatic squamous cell carcinoma of the anal canal. Eng C; Chang GJ; You YN; Das P; Rodriguez-Bigas M; Xing Y; Vauthey JN; Rogers JE; Ohinata A; Pathak P; Sethi S; Phillips JK; Crane CH; Wolff RA Oncotarget; 2014 Nov; 5(22):11133-42. PubMed ID: 25373735 [TBL] [Abstract][Full Text] [Related]
7. Second-line treatment after docetaxel, cisplatin and 5-fluorouracil in metastatic squamous cell carcinomas of the anus. Pooled analysis of prospective Epitopes-HPV01 and Epitopes-HPV02 studies. Stouvenot M; Meurisse A; Saint A; Buecher B; André T; Samalin E; Jary M; El Hajbi F; Baba-Hamed N; Pernot S; Kaminsky MC; Bouché O; Desrame J; Zoubir M; Smith D; Ghiringhelli F; Parzy A; de la Fouchardiere C; Almotlak H; Vienot A; Jacquin M; Taieb J; Nguyen T; Vernerey D; Borg C; Kim S Eur J Cancer; 2022 Feb; 162():138-147. PubMed ID: 34995900 [TBL] [Abstract][Full Text] [Related]
8. Single-agent paclitaxel in advanced anal cancer after failure of cisplatin and 5-fluorouracil chemotherapy. Abbas A; Nehme E; Fakih M Anticancer Res; 2011 Dec; 31(12):4637-40. PubMed ID: 22199342 [TBL] [Abstract][Full Text] [Related]
9. Mitomycin and 5-fluorouracil for second-line treatment of metastatic squamous cell carcinomas of the anal canal. Saint A; Evesque L; Falk AT; Cavaglione G; Montagne L; Benezery K; Francois E Cancer Med; 2019 Nov; 8(16):6853-6859. PubMed ID: 31524335 [TBL] [Abstract][Full Text] [Related]
10. [Epidermoid carcinomas of anal canal treated with radiation therapy and concomitant chemotherapy (5-fluorouracil and cisplatin)]. Deniaud-Alexandre E; Touboul E; Tiret E; Sezeur A; Hannoun L; Houry S; Huguet F; Pène F; Parc R; Schlienger M Cancer Radiother; 2006 Dec; 10(8):572-82. PubMed ID: 17110148 [TBL] [Abstract][Full Text] [Related]
11. Case report of long term survivor of metastatic cloacogenic carcinoma of the anal canal with chemotherapy. Fayaz S; Vasishta S; Motawy M Gulf J Oncolog; 2007 Jul; (2):65-8. PubMed ID: 20084726 [TBL] [Abstract][Full Text] [Related]
12. New approaches in palliative systemic therapy of anal squamous cell carcinoma. Lohynská R; Pechačová Z Klin Onkol; 2022; 35(3):190-194. PubMed ID: 35760571 [TBL] [Abstract][Full Text] [Related]
13. Definitive chemoradiotherapy for anal canal cancer: single-center experience. Tachibana I; Nishimura Y; Inada M; Fukuda K; Ishikawa K; Nishikawa T; Yokokawa M; Nakamatsu K; Kanamori S; Hida JI Int J Clin Oncol; 2018 Dec; 23(6):1121-1126. PubMed ID: 29992389 [TBL] [Abstract][Full Text] [Related]
14. DCF (docetaxel, cisplatin and 5-fluorouracil) chemotherapy is a promising treatment for recurrent advanced squamous cell anal carcinoma. Kim S; Jary M; Mansi L; Benzidane B; Cazorla A; Demarchi M; Nguyen T; Kaliski A; Delabrousse E; Bonnetain F; Letondal P; Bosset JF; Valmary-Degano S; Borg C Ann Oncol; 2013 Dec; 24(12):3045-50. PubMed ID: 24114858 [TBL] [Abstract][Full Text] [Related]
16. Docetaxel, Cisplatin, and 5-fluorouracil (DCF) chemotherapy in the treatment of metastatic or unresectable locally recurrent anal squamous cell carcinoma: a phase II study of French interdisciplinary GERCOR and FFCD groups (Epitopes-HPV02 study). Kim S; Jary M; André T; Vendrely V; Buecher B; François E; Bidard FC; Dumont S; Samalin E; Peiffert D; Pernot S; Baba-Hamed N; El Hajbi F; Bouché O; Desrame J; Parzy A; Zoubir M; Louvet C; Bachet JB; Nguyen T; Abdelghani MB; Smith D; De La Fouchardière C; Aparicio T; Bennouna J; Gornet JM; Jacquin M; Bonnetain F; Borg C BMC Cancer; 2017 Aug; 17(1):574. PubMed ID: 28841909 [TBL] [Abstract][Full Text] [Related]
17. [Squamous cell anal carcinoma. What's next ?]. Kim S; Spehner L; Cabel L; Bidard FC; Borg C Bull Cancer; 2021 Jan; 108(1):80-89. PubMed ID: 33423780 [TBL] [Abstract][Full Text] [Related]
18. Carboplatin and paclitaxel treatment is effective in advanced anal cancer. Kim R; Byer J; Fulp WJ; Mahipal A; Dinwoodie W; Shibata D Oncology; 2014; 87(2):125-32. PubMed ID: 25012155 [TBL] [Abstract][Full Text] [Related]